Nama's AI scorecard currently rates Vor Biopharma Sell (2.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is VOR's P/E ratio?

Vor Biopharma trades at a trailing price-to-earnings ratio of 0.1.

When does VOR report earnings?

Vor Biopharma's next scheduled report is on Mar 16, 2027. Analysts expect EPS of -$0.81.

What is the VOR price target?

The median analyst price target from 8 analysts is $40.00, with a range of $27.00 – $50.00.

Is VOR Shariah compliant?

Nama's AAOIFI-style screen reads Vor Biopharma as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Vor Biopharma (VOR)

Healthcare · Biotechnology · NASDAQ

Vor Biopharma (VOR) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.22B, a trailing price-to-earnings ratio of 0.1 and a free-cash-flow yield of -73.2%. Nama's AI scorecard rates it Sell, 2.2 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 2.2/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Lagging · -1.0% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-94.6%

How far the last close sits under the highest price of the past five years.

Market cap	$1.22B
Trailing P/E	0.1
Price / book	—
Price / sales	—
FCF yield	-73.2%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

VOR earnings

Next report: Mar 16, 2027 (Q4 2026, EPS estimate -$0.81). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 30, 2026	-$0.90	-$0.72	-25.0%	$0
Q2 2026	Aug 11, 2026	-$0.80	-$0.70	-14.3%	$0
Q1 2026	May 13, 2026	-$0.73	-$0.78	+6.4%	$0
Q4 2025	Mar 30, 2026	$307.53	-$1.19	+25942.9%	$0

VOR analyst price target

Median target $40.00 from 8 analysts, ranging $27.00 – $50.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live VOR data on Nama Insights →

VOR FAQ

Is VOR a buy?: Nama's AI scorecard currently rates Vor Biopharma Sell (2.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is VOR's P/E ratio?: Vor Biopharma trades at a trailing price-to-earnings ratio of 0.1.
When does VOR report earnings?: Vor Biopharma's next scheduled report is on Mar 16, 2027. Analysts expect EPS of -$0.81.
What is the VOR price target?: The median analyst price target from 8 analysts is $40.00, with a range of $27.00 – $50.00.
Is VOR Shariah compliant?: Nama's AAOIFI-style screen reads Vor Biopharma as Not Shariah Compliant. At least one of the three ratios or the industry test failed.